• 1
    Pawlosky RJ, Denkins Y, Ward G, Salem N Jr. Retinal and brain accretion of long-chain polyunsaturated fatty acids in developing felines: the effects of corn oil-based maternal diets. Am J Clin Nutr 1997; 65: 46572.
  • 2
    Hashimoto M, Tanabe Y, Fujii Y, Kikuta T, Shibata H, Shido O. Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J Nutr 2005; 135: 54955.
  • 3
    Lin DS, Connor WE, Anderson GJ, Neuringer M. Effects of dietary n-3 fatty acids on the phospholipid molecular species of monkey brain. J Neurochem 1990; 55: 12007.
  • 4
    Anderson GJ, Neuringer M, Lin DS, Connor WE. Can prenatal N-3 fatty acid deficiency be completely reversed after birth? Effects on retinal and brain biochemistry and visual function in rhesus monkeys. Pediatr Res 2005; 58: 86572.
  • 5
    Söderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991; 26: 4215.
  • 6
    Martín V, Fabelo N, Santpere G et al. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis 2010; 19: 489502.
  • 7
    Tully AM, Roche HM, Doyle R. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case–control study. Br J Nutr 2003; 89: 4839.
  • 8
    McNamara RK. DHA deficiency and prefrontal cortex neuropathology in recurrent affective disorders. J Nutr 2010; 140: 8648.
  • 9
    Cederholm T, Palmblad J. Are omega-3 fatty acids options for prevention and treatment of cognitive decline and dementia? Curr Opin Clin Nutr Metab Care 2010; 13: 1505.
  • 10
    Schaefer EJ, Bongard V, Beiser AS et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006; 63: 154550.
  • 11
    Freund Levi Y, Eriksdotter-Jönhagen M, Cederholm T et al. Omega-3 fatty acid supplementation delays the cognitive decline in patients with very mild Alzheimer's disease – a 1-year randomized placebo-controlled study of 174 patients. Arch Neurol 2006; 63: 14028.
  • 12
    Yurko-Mauro K, McCarthy D, Rom D et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010; 6: 45664.
  • 13
    Sarris J, Mischoulon D, Schweitzer J. Omega-3 for bipolar disorder: metaanalyses of use in mania and bipolar depression. J Clin Psychiatry 2012; 73: 816.
  • 14
    Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 2007; 85: 110311.
  • 15
    Heude B, Ducimetière P, Berr C; EVA Study. Cognitive decline and fatty acid composition of erythrocyte membranes. The EVA Study. Am J Clin Nutr 2003; 77: 8038.
  • 16
    Quinn JF, Raman R, Thomas RG. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease. A randomized trial. JAMA 2010; 304: 190311.
  • 17
    Freund Levi Y, Hjort E, Lindberg C et al. Effects of omega-3 fatty acids on inflammatory markers in CSF and plasma in Alzheimer's disease. The OmegAD study. Dement Geriatr Cogn Disord 2009; 27: 48190.
  • 18
    Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 9117.
  • 19
    Morrison WR, Smith LM. Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron-fluoride methanol. J Lipid Res 1964; 5: 6008.
  • 20
    Pilitsis JG, Diaz FG, Wellwood JM et al. Quantification of free fatty acids in human cerebrospinal fluid. Neurochem Res 2001; 26: 126570.
  • 21
    Rapoport SI. Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostaglandins Leukot Essent Fatty Acids 2008; 79: 1536.
  • 22
    Perez SE, Berg BM, Moore KA et al. DHA diet reduces AD pathology in young APPswe/PS1 Delta E9 transgenic mice: possible gender effects. J Neurosci Res 2010; 88: 102640.
  • 23
    Hooijmans CR, Van der Zee CE, Dederen PJ et al. DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 2009; 33: 48298.
  • 24
    Green KN, Martinez-Coria H, Khashwji H et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 2007; 27: 438595.
  • 25
    Calon F, Lim GP, Yang F et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004; 43: 63345.
  • 26
    Oksman M, Iivonen H, Hogyes E et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 2006; 23: 56372.
  • 27
    Hashimoto M, Hossain S, Agdul H, Shido O. Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions. Biochim Biophys Acta 2005; 1738: 918.
  • 28
    Lim GP, Calon F, Morihara T et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005; 25: 303240.
  • 29
    Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 13144.
  • 30
    Scheltens P, Kamphuis PJ, Verhey FR et al. Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimers Dement 2010; 6: 110.
  • 31
    Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 34961.
  • 32
    Ouellet M, Emond V, Chen CT et al. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood–brain barrier: an in situ cerebral perfusion study. Neurochem Int 2009; 55: 47682.
  • 33
    Umhau JC, Zhou W, Carson RE et al. Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. J Lipid Res 2009; 50: 125968.
  • 34
    Oreskovic D, Klarica M. The formation of cerebrospinal fluid: nearly a hundred years of interpretations and misinterpretations. Brain Res Rev 2010; 64: 24162.
  • 35
    Engelhardt B, Sorokin L. The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 2009; 31: 497511.
  • 36
    Chen CT, Green JT, Orr SK, Bazinet RP. Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukot Essent Fatty Acids 2008; 79: 8591.
  • 37
    Chen CT, Liu Z, Bazinet RP. Rapid de-esterification and loss of eicosapentaenoic acid from rat brain phospholipids: an intracerebroventricular study. J Neurochem 2011; 116: 36373.
  • 38
    Chen CT, Liu Z, Ouellet M, Calon F, Bazinet RP. Rapid beta-oxidation of eicosapentaenoic acid in mouse brain: an in situ study. Prostaglandins Leukot Essent Fatty Acids 2009; 80: 15763.
  • 39
    Mazereeuw G, Lanctôt KL, Chau SA, Swardfager W, Herrmann N. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Ageing 2012; 33: 1482.e1729.